MXPA02012574A - Uso novedoso de los antagonistas ii de angiotensina. - Google Patents
Uso novedoso de los antagonistas ii de angiotensina.Info
- Publication number
- MXPA02012574A MXPA02012574A MXPA02012574A MXPA02012574A MXPA02012574A MX PA02012574 A MXPA02012574 A MX PA02012574A MX PA02012574 A MXPA02012574 A MX PA02012574A MX PA02012574 A MXPA02012574 A MX PA02012574A MX PA02012574 A MXPA02012574 A MX PA02012574A
- Authority
- MX
- Mexico
- Prior art keywords
- angiotensin
- antagonists
- vascular headache
- new use
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Mattresses And Other Support Structures For Chairs And Beds (AREA)
Abstract
La presente invencion se refiere al uso de un antagonista del receptor 1 del tipo II de angiotensina de la formula general (I) en la obtencion de un medicamento para el tratamiento terapeutico y/o profilactico de una condicion de dolor de cabeza vascular tal como migrana, en un sujeto que sufre de lo mismo, o que es susceptible a tal condicion de dolor de cabeza vascular. Un aspecto adicional de la invencion es una formulacion farmaceutica util en cualquiera de las condiciones de dolor de cabeza vascular, asi tambien como un metodo para el tratamiento del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0002353A SE0002353D0 (sv) | 2000-06-22 | 2000-06-22 | New use |
PCT/SE2001/001379 WO2001097807A1 (en) | 2000-06-22 | 2001-06-15 | New use of angiotensin ii antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA02012574A true MXPA02012574A (es) | 2003-04-10 |
Family
ID=20280208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA02012574A MXPA02012574A (es) | 2000-06-22 | 2001-06-15 | Uso novedoso de los antagonistas ii de angiotensina. |
Country Status (21)
Country | Link |
---|---|
US (1) | US7872035B2 (es) |
EP (2) | EP1307192B1 (es) |
JP (1) | JP2003535897A (es) |
KR (1) | KR100692235B1 (es) |
CN (2) | CN1250218C (es) |
AT (1) | ATE318597T1 (es) |
AU (2) | AU7476501A (es) |
BR (1) | BR0111900A (es) |
CA (1) | CA2411553A1 (es) |
DE (1) | DE60117541T2 (es) |
DK (1) | DK1307192T3 (es) |
ES (1) | ES2257416T3 (es) |
HK (1) | HK1053609A1 (es) |
IL (2) | IL153158A0 (es) |
MX (1) | MXPA02012574A (es) |
NO (1) | NO330300B1 (es) |
NZ (1) | NZ523048A (es) |
PT (1) | PT1307192E (es) |
SE (1) | SE0002353D0 (es) |
WO (1) | WO2001097807A1 (es) |
ZA (1) | ZA200209902B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040097565A1 (en) * | 2001-01-29 | 2004-05-20 | Terashita Zen-Ichi | Analgesic and antiinflammatory drugs |
US20050065094A1 (en) * | 2003-09-05 | 2005-03-24 | Boehringer Ingelheim International Gmbh | Use of telmisartan for the prevention and treatment of vascular headache |
FR2892803B1 (fr) | 2005-10-28 | 2008-04-04 | Valeo Systemes Thermiques | Boite collectrice pour echangeur de chaleur, notamment pour evaporateur de climatisation, echangeur comportant une telle boite |
JP5468420B2 (ja) * | 2010-03-04 | 2014-04-09 | 株式会社マキタ | 手持ち式切断工具 |
US20140057955A1 (en) | 2011-03-30 | 2014-02-27 | The Johns Hopkins University | Novel, protective, anti-inflammatory receptor and its use in preservation of mitochondrial function, wound healing and repair |
KR20130074808A (ko) | 2011-12-16 | 2013-07-05 | 한올바이오파마주식회사 | 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물 |
TWI754772B (zh) * | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
US5703110A (en) * | 1990-04-27 | 1997-12-30 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
US5241009A (en) | 1990-05-07 | 1993-08-31 | Kimberly-Clark Corporation | Polymeric composition containing carboxy nueutralized with lithium or potassium |
CA2041763A1 (en) * | 1990-05-11 | 1991-11-12 | Sheih-Shung T. Chen | Microbial transformation process for antihypertensive products |
US5128327A (en) * | 1991-03-25 | 1992-07-07 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle |
US5177074A (en) * | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
US5214153A (en) * | 1992-04-23 | 1993-05-25 | Merck & Co., Inc. | Actinoplanes transformation process anti-hypertensive compound and method of use thereas |
-
2000
- 2000-06-22 SE SE0002353A patent/SE0002353D0/xx unknown
-
2001
- 2001-06-15 US US10/311,760 patent/US7872035B2/en not_active Expired - Fee Related
- 2001-06-15 WO PCT/SE2001/001379 patent/WO2001097807A1/en active IP Right Grant
- 2001-06-15 IL IL15315801A patent/IL153158A0/xx not_active IP Right Cessation
- 2001-06-15 ES ES01941408T patent/ES2257416T3/es not_active Expired - Lifetime
- 2001-06-15 DE DE60117541T patent/DE60117541T2/de not_active Expired - Lifetime
- 2001-06-15 CN CNB018142788A patent/CN1250218C/zh not_active Expired - Fee Related
- 2001-06-15 KR KR1020027017396A patent/KR100692235B1/ko not_active IP Right Cessation
- 2001-06-15 MX MXPA02012574A patent/MXPA02012574A/es active IP Right Grant
- 2001-06-15 CN CNA2006100088164A patent/CN1846697A/zh active Pending
- 2001-06-15 EP EP01941408A patent/EP1307192B1/en not_active Expired - Lifetime
- 2001-06-15 BR BR0111900-1A patent/BR0111900A/pt not_active IP Right Cessation
- 2001-06-15 AU AU7476501A patent/AU7476501A/xx active Pending
- 2001-06-15 JP JP2002503291A patent/JP2003535897A/ja active Pending
- 2001-06-15 EP EP05028367A patent/EP1656940A1/en not_active Withdrawn
- 2001-06-15 NZ NZ523048A patent/NZ523048A/en not_active IP Right Cessation
- 2001-06-15 DK DK01941408T patent/DK1307192T3/da active
- 2001-06-15 PT PT01941408T patent/PT1307192E/pt unknown
- 2001-06-15 AT AT01941408T patent/ATE318597T1/de active
- 2001-06-15 AU AU2001274765A patent/AU2001274765B2/en not_active Ceased
- 2001-06-15 CA CA002411553A patent/CA2411553A1/en not_active Abandoned
-
2002
- 2002-11-28 IL IL153158A patent/IL153158A/en unknown
- 2002-12-05 ZA ZA200209902A patent/ZA200209902B/en unknown
- 2002-12-18 NO NO20026085A patent/NO330300B1/no not_active IP Right Cessation
-
2003
- 2003-08-19 HK HK03105920A patent/HK1053609A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1846697A (zh) | 2006-10-18 |
NO20026085D0 (no) | 2002-12-18 |
SE0002353D0 (sv) | 2000-06-22 |
EP1307192A1 (en) | 2003-05-07 |
EP1307192B1 (en) | 2006-03-01 |
NO330300B1 (no) | 2011-03-28 |
CN1250218C (zh) | 2006-04-12 |
CA2411553A1 (en) | 2001-12-27 |
NO20026085L (no) | 2002-12-18 |
AU2001274765B2 (en) | 2005-08-18 |
US7872035B2 (en) | 2011-01-18 |
DE60117541D1 (de) | 2006-04-27 |
DE60117541T2 (de) | 2006-09-14 |
ES2257416T3 (es) | 2006-08-01 |
ATE318597T1 (de) | 2006-03-15 |
IL153158A0 (en) | 2003-06-24 |
HK1053609A1 (en) | 2003-10-31 |
EP1656940A1 (en) | 2006-05-17 |
ZA200209902B (en) | 2004-03-05 |
KR100692235B1 (ko) | 2007-03-09 |
BR0111900A (pt) | 2003-05-13 |
IL153158A (en) | 2008-03-20 |
PT1307192E (pt) | 2006-06-30 |
JP2003535897A (ja) | 2003-12-02 |
US20040092563A1 (en) | 2004-05-13 |
AU7476501A (en) | 2002-01-02 |
WO2001097807A1 (en) | 2001-12-27 |
NZ523048A (en) | 2004-09-24 |
CN1447693A (zh) | 2003-10-08 |
DK1307192T3 (da) | 2006-06-12 |
KR20030019444A (ko) | 2003-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005013894A3 (en) | Benzodiazepine cgrp receptor antagonists | |
TW200505903A (en) | CGRP receptor antagonists | |
JO2371B1 (en) | 4-phenyl-pyridine derivatives | |
NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
WO2005000807A3 (en) | Benzodiazepine cgrp receptor antagonists | |
HK1069339A1 (en) | Substituted diketopiperazines as oxytocin antagonists | |
EP1615914A4 (en) | CGRP RECEPTOR ANTAGONISTS | |
MY133503A (en) | Selective iglur5 receptor antagonists for the treatment of migrane | |
WO2002060392A3 (en) | Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
EP1064966A3 (en) | Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine | |
AU2001290480A1 (en) | Cyclized benzamide neurokinin antagonists for use in therapy | |
MXPA01008993A (es) | Tratamiento de combinacion para depresion y ansiedad. | |
MXPA02012574A (es) | Uso novedoso de los antagonistas ii de angiotensina. | |
SE9902597D0 (sv) | New use | |
CA2432177A1 (en) | Drug for prevention and/or therapy of endometriosis | |
RS78004A (en) | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | |
EA200300850A1 (ru) | Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах | |
WO2002053099A3 (en) | Methods and compositions for treating periodontal disease | |
MXPA04004450A (es) | Nuevos compuestos y composiciones como inhibidores de catepsina s. | |
EP1064948A3 (en) | Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine | |
EP1095655A3 (en) | NK-1 receptor antagonists and eletriptan for the treatment of migraine | |
SG143979A1 (en) | Novel compounds and compositions as cathepsin inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |